I really want to believe in both Chai Discovery and Precigenetics. But the one thing connecting today’s two stories is that conviction is arriving before public proof.

Chai says its models can turn antibody discovery from a long search into a more programmable process, and Lilly, Pfizer and Novartis have seen enough to sign on.

Precigenetics points toward a future beyond biology’s dark ages. One day, we may look back in disbelief at how researchers had to kill, fix or break cells apart to understand them.

In both cases, however, we are being asked to peer through a partly closed door and decide how excited to get.

Let’s dive in.